Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: Reflecting on the First Year of My Column, ‘Mutations & Conversations’ Armata Announces New Treatment Candidate for P. Aeruginosa Infections in CF Patients Reflecting on the First Year of My Column, ‘Mutations & Conversations’ Sep 16, 2019 09:00 am | Tré LaRosa This column was my first official writing gig. I started my blog almost three years ago, but my posts were inconsistent and didn’t have a clear voice. “Mutations & Conversations” provided me with a space to write about the many facets of life with cystic fibrosis (CF) without overly worrying about the identity of my […] The post Reflecting on the First Year of My Column, ‘Mutations & Conversations’ appeared first on Cystic Fibrosis News Today. Read More Armata Announces New Treatment Candidate for P. Aeruginosa Infections in CF Patients Sep 16, 2019 07:00 am | Steve Bryson PhD Armata Pharmaceuticals is going to target multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients with its new enhanced bacteriophage candidate AP-PA02, the company announced. AP-PA02 is being developed to replace the company’s candidate AP-PA01, which was shown to successfully treat a CF patient with resistant P. aeruginosa infection. “The successful case study recently published in Infection […] The post Armata Announces New Treatment Candidate for P. Aeruginosa Infections in CF Patients appeared first on Cystic Fibrosis News Today. Read More Recent News New Agreement in Scotland Grants CF Patients Access to Orkambi and Symkevi Safety, Early Effectiveness of POL6014 Confirmed in Phase 1 Trial ICER Seeking Feedback on CF Treatments from Stakeholders I Don’t Identify with the Word Disabled Drexel Study to Look at Tailored ‘Talk’ Therapy in Helping Ease Depression and Anxiety in CF Patients